

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 13D/A**  
(Rule 13d-101)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(a)**

**Under the Securities Exchange Act of 1934  
(Amendment No. 2)**

---

**Aerpio Pharmaceuticals, Inc.**

(Name of issuer)

**Common Stock, par value \$0.0001**  
(Title of class of securities)

**00810B105**  
(CUSIP number)

**Muneer A. Satter**  
c/o Satter Management Co., L.P.  
676 N. Michigan Avenue, Suite 4000, Chicago, IL 60611  
(312) 448-5500

***COPY TO:***

**Robert M. Hayward, P.C.**  
**Kirkland & Ellis LLP**  
300 N. LaSalle St.  
Chicago, Illinois 60654  
(312) 862-2000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**January 10, 2019**  
(Date of Event which Requires Filing of this Statement)

---

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.

---

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

---

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

## SCHEDULE 13D

CUSIP No. 00810B105

Page 2 of 4

**Explanatory Note:** The Schedule 13D originally filed by the Reporting Person with the Securities and Exchange Commission ("SEC") on March 27, 2017, and as amended by Amendment No. 1 to Schedule 13D filed with the SEC on July 3, 2018 (collectively the "Prior Filings"), is hereby amended by this Amendment No. 2 to Schedule 13D ("Amendment"). Capitalized terms used herein and not otherwise defined have the meanings assigned to such terms in the Prior Filings.

(1)	Names of reporting persons  Muneer A. Satter	
(2)	Check the appropriate box if a member of a group (see instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
(3)	SEC use only	
(4)	Source of funds (see instructions)  PF; OO	
(5)	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
(6)	Citizenship or place of organization  United States of America	
Number of shares beneficially owned by each reporting person with:	(7)	Sole voting power  5,621,835 shares (see Item 5(a))
	(8)	Shared voting power  0 shares
	(9)	Sole dispositive power  5,621,835 shares (see Item 5(a))
	(10)	Shared dispositive power  0 shares
(11)	Aggregate amount beneficially owned by each reporting person  5,621,835 shares (see Item 5(a))	
(12)	Check if the aggregate amount in Row (11) excludes certain shares (see instructions) <input type="checkbox"/>	
(13)	Percent of class represented by amount in Row (11)  13.9%	
(14)	Type of reporting person (see instructions)  IN	

**Item 3. Source and Amount of Funds.**

*Item 3 of the Prior Filings is amended by adding the following paragraph:*

Between November 28, 2018 and January 10, 2019, SMTP purchased in the open market an aggregate of 543,818 shares of Common Stock in multiple transactions at weighted average prices ranging from \$1.6705 to \$2.4537. The source of funds for the acquisition of shares in the open market was capital committed by the partners of SMTP.

**Item 5. Interest in Securities of the Issuer.**

*Paragraph (a) of Item 5 of the Prior Filings is hereby deleted and replaced as follows:*

(a) *Amount beneficially owned as of the date hereof:*

In the aggregate, the Reporting Person beneficially owns 5,621,835 shares of Common Stock, consisting of (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares and (c) 3,500,000 shares that are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person also holds stock options to purchase 21,400 shares of Common Stock, which vest on the earlier of the one year anniversary of the date of grant (June 20, 2019) or the Company's next annual meeting.

*Percent of class:*

In the aggregate, the Reporting Persons beneficially own 5,621,835 shares of Common Stock, or 13.9% of the total number of shares of Common Stock outstanding.

All percentages calculated in this Schedule 13D are based upon 40,588,004 shares outstanding as of December 27, 2018, as disclosed in the Company's Form S-3 Registration Statement filed with the Securities and Exchange Commission ("*SEC*") on December 28, 2018.

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 11, 2019

By: /s/ Muneer A. Satter  
Muneer A. Satter